Eden Research PLC - AIM-listed biopesticides and plastic-free formulation technology company for use in the global crop protection, animal health and consumer products industries - Posts revenue of £1.8 million for 2022, up from £1.2 million in 2021. Pretax loss narrows to £2.6 million from £3.4 million, as gross profit increases to £830,160 from £561,237 a year earlier. Looking ahead, says it is working hard to move forward with new products including insecticides, seed treatments, and optimised fungicides.

Chair Lykele van der Broek says: ‘2022 was a positive year for Eden with a return to strong sales growth and approval for Eden’s two commercial products, Mevalone and Cedroza, and three active ingredients granted approval in the US. 2023 looks set to provide a number of significant opportunities including further territorial expansion and targeted diseases, increased products sales, and the continued development of other product lines such as our seed treatment and insecticide projects.’

Current stock price: 4.87 pence each, up 2.6% on Friday morning in London

12-month change: 0.5%

Copyright 2023 Alliance News Ltd. All Rights Reserved.